Financial Enhancement Group LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 9.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,616 shares of the biotechnology company’s stock after purchasing an additional 1,567 shares during the period. Financial Enhancement Group LLC’s holdings in United Therapeutics were worth $3,947,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Belpointe Asset Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $82,000. JPMorgan Chase & Co. raised its position in shares of United Therapeutics by 1.3% in the 4th quarter. JPMorgan Chase & Co. now owns 182,217 shares of the biotechnology company’s stock worth $50,673,000 after buying an additional 2,279 shares during the period. BI Asset Management Fondsmaeglerselskab A S boosted its holdings in United Therapeutics by 204.1% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,302 shares of the biotechnology company’s stock valued at $740,000 after acquiring an additional 2,216 shares during the last quarter. Pictet Asset Management SA grew its position in United Therapeutics by 1.3% during the first quarter. Pictet Asset Management SA now owns 288,418 shares of the biotechnology company’s stock valued at $64,594,000 after acquiring an additional 3,766 shares during the period. Finally, Ronald Blue Trust Inc. increased its stake in United Therapeutics by 49.1% during the first quarter. Ronald Blue Trust Inc. now owns 1,375 shares of the biotechnology company’s stock worth $382,000 after acquiring an additional 453 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Stock Down 0.7 %
UTHR stock opened at $223.78 on Wednesday. The company has a market capitalization of $10.50 billion, a P/E ratio of 12.66 and a beta of 0.62. The firm has a 50 day simple moving average of $232.12 and a 200-day simple moving average of $226.34. The company has a current ratio of 8.68, a quick ratio of 8.40 and a debt-to-equity ratio of 0.15. United Therapeutics Co. has a twelve month low of $201.65 and a twelve month high of $283.09.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Wedbush boosted their target price on United Therapeutics from $305.00 to $307.00 and gave the stock an “outperform” rating in a report on Thursday, August 3rd. LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $256.00 to $268.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, August 3rd. Morgan Stanley increased their target price on United Therapeutics from $316.00 to $318.00 and gave the company an “overweight” rating in a research note on Thursday, August 3rd. Finally, StockNews.com assumed coverage on United Therapeutics in a research report on Thursday, August 17th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $296.44.
Read Our Latest Stock Analysis on UTHR
Insider Transactions at United Therapeutics
In related news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $222.98, for a total transaction of $1,337,880.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at $8,160,845.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $222.98, for a total value of $1,337,880.00. Following the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,160,845.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 2,500 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $243.87, for a total value of $609,675.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at $8,925,398.13. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,500 shares of company stock worth $6,022,815. 12.50% of the stock is currently owned by insiders.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
- Five stocks we like better than United Therapeutics
- How to Invest in Artificial Intelligence
- Ray Dalio’s Move into 3 Stocks, All Betting on One Thing
- How to Invest in the Entertainment Industry
- Airbnb Joins the S&P 500, Time to Buy In?
- Energy and Oil Stocks Explained
- Does Dell Technologies Blowout Quarter Mean a New Demand Cycle?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
